- Clene Inc (NASDAQ:CLNN) announced new results from exploratory analyses, including delayed time to key clinical progression events in amyotrophic lateral sclerosis (ALS) patients treated with CNM-Au8 in the HEALEY ALS Platform Trial over the 6-months.
- ALS is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing a loss of muscle control.
- ALS is often called Lou Gehrig’s disease, after the baseball player diagnosed with it.
- Related: Clene’s Lead Amyotrophic Lateral Sclerosis Shows Improved Function, Slowed Disease Progression.
- Analyses of prespecified exploratory endpoints from the HEALEY ALS Platform Trial suggest that treatment with CNM-Au8 delayed time to ALS clinical worsening events across all domains, including the need for assisted breathing and placement of stomach feeding tubes.
- A 74% decreased risk (lower hazard) of the composite endpoint of time to ALS clinical worsening, which included the first instance of death, tracheostomy, initiation of permanent assisted ventilation, or placement of a feeding tube.
- Treatment with CNM-Au8 was also associated with statistically significant and directional trends across all prespecified time to clinical worsening event analyses.
- 98% decreased risk (lower hazard) of death or permanently assisted ventilation.
- 95% decreased risk of death.
- 74% decreased risk of feeding tube placement.
- 63% decreased risk of assisted ventilation.
- 84% decreased risk of ALS-related hospitalization.
- 69% decreased risk of all-cause hospitalization.
- Price Action: CLNN shares are up 6.22% at $1.38 during the market session on the last check Thursday.
Stifel Maintains Buy on Meta Platforms, Raises Price Target to $210
Stifel analyst Mark Kelley maintains Meta Platforms (NASDAQ:META) with a Buy and raises the price target from $180 to $210.
